Abstract:We present a combined imaging system of positron emission tomography (PET) and electron paramagnetic resonance imaging (EPRI) developed for assessing tumor hypoxia. Tumor hypoxia has been known to be resistant for cancer treatment such as radiation therapy. Therefore, precise quantitative measurement of tumor hypoxia is important for effective cancer treatment planning in radiation therapy. In clinic, PET imaging by using 18 F-fluoromisonidazole (F-MISO) have been performed to delineate tumor hypoxia. However, the effectiveness of PET imaging based hypoxia targeting in radiation therapy was not yet firmly established. EPRI is a non-invasive imaging method capable of measuring the partial pressure of oxygen (pO 2 ) in tissue precisely. However, EPRI is not available for clinical use currently. The combined imaging system is to use EPRI as a gold standard to measure the pO 2 in hypoxic tumor in animal, and aims to evaluate the validity of PET imaging in tumor hypoxia by simultaneously acquired EPRI. The PET component of the combined system, which was originally developed as an insert for MRI, consists of total 14 detector modules. Each PET detector module uses of 8×4 LYSO arrays (3×3×10 mm 3 ) coupled to Hamamatsu S13361 MPPC arrays (3.2 mm pitch). The detector modules are encased in a cylindrical plastic holder with 60 mm inner diameter and 115 mm outer diameter in a ring configuration. The axial field of view of the PET is 25.6 mm. The EPRI component of the system is built with two permanent magnets (25 mT), three gradient field coils for spatial encoding (the maximum 15 mT/m) and a RF resonator. The PET is installed to fit into the two EPR magnets (12 cm distance apart) so that the PET detector center is aligned to the magnet center. The compatibility of two imaging modalities were tested by using a 22 Na point source and imaging phantoms. Animal imaging with F-MISO and FDG were also performed by running the PET/EPR simultaneously. Initial imaging results are reported.

Development of a PET/EPRI combined imaging system for assessing tumor hypoxia

A PET/EPR simultaneous imaging system for assessing tumor hypoxia: development and initial imaging results

Positron Emission Tomography Imaging of Tumor Hypoxia

Imaging of Tumor Hypoxia With Radionuclide-Labeled Tracers for PET

The optimal 18F-fluoromisonidazole PET threshold to define tumor hypoxia in preclinical squamous cell carcinomas using pO2 electron paramagnetic resonance imaging as reference truth

Development of Novel 18F-PET Agents for Tumor Hypoxia Imaging.

Image-guided PO2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats

Quantitative hypoxia imaging for treatment planning of radiotherapy

PET Hypoxia Imaging and Progress of Enhancing Radio-Sensitivity in Hypoxic Tumor

Validation of the design of a high-sensitivity and high-resolution PET system for a preclinical PET/EPR hybrid scanner

Development of a Hypoxia-Activated Red-Emission Fluorescent Probe for in Vivo Tumor Microenvironment Imaging and Anti-Tumor Therapy

18F-HX4/18F-FMISO-based micro PET for imaging of tumor hypoxia and radiotherapy-associated changes in mice

Positron Emission Tomography Imaging Sheds New Light on Hypoxia and Antitumor Therapies

Monitoring Tumor Hypoxia Using 18 F-FMISO PET and Pharmacokinetics Modeling after Photodynamic Therapy

Monitoring Tumor Hypoxia Using F-18-Fmiso Pet And Pharmacokinetics Modeling After Photodynamic Therapy

The Application of Hypoxia Imaging with PET in Predicting Tumor Hypoxia and Guiding Clinical Therapy

Advances in PET and MRI imaging of tumor hypoxia

A Hybrid Imaging Platform(CT/PET/FMI) for Evaluating Tumor Necrosis and Apoptosis in Real-Time

Hypoxia-triggered single molecule probe for high-contrast NIR II/PA tumor imaging and robust photothermal therapy

Supplementary Data from A Near-Infrared Phosphorescent Nanoprobe Enables Quantitative, Longitudinal Imaging of Tumor Hypoxia Dynamics During Radiotherapy

Evaluations of an Early Change in Tumor Pathophysiology in Response to Radiotherapy with Oxygen Enhanced Electron Paramagnetic Resonance Imaging (OE EPRI)